Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
SonoThera logo — SonoThera is developing ultrasound-mediated nonviral genetic...

SonoThera

SonoThera is developing ultrasound-mediated nonviral genetic therapies.

Founded 2021 United States South San Francisco, United States 54 employees Series A Total: $60.75M Biopharma, Biotechnology

General Information

Company Name SonoThera
Founded Year 2021
Location United States South San Francisco, United States
Employees 54
Industries Biopharma, Biotechnology
Funding Stage Series A
Business Model B2B, B2D
Revenue Model Licensing, Service Fee, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with SonoThera. To contact SonoThera, visit sonothera.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SonoThera compare?

A PDF of SonoThera and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SonoThera soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SonoThera

SonoThera is a promising player in the Biopharma and Biotechnology industries, founded in 2021 and headquartered in the United States. The company is carving a niche by developing ultrasound-mediated nonviral genetic therapies, a cutting-edge technological approach that sets it apart in the competitive biotech landscape.

The potential impact of SonoThera's technology in personalized medicine and genetic therapy is substantial, offering scalable and potentially safer alternatives to existing viral vector technologies. This innovation has captured significant attention, as reflected in its substantial $60.75M Series A investment dated 01 December 2022.

The investment was spearheaded by an impressive cohort of investors, including Foothill Ventures, Arch Venture Partners, Johnson & Johnson Innovation, Illumina Ventures, among others, showcasing strong market confidence in SonoThera's growth potential and strategic vision.

Business keywords: ultrasound-mediated therapies, nonviral genetic therapies, genetic medicine, disease treatment innovation, gene therapy, ultrasound technology, therapeutic development, advanced drug delivery, biomedical research, genetic engineering, precision medicine

Services & Products

Development of Ultrasound-Mediated Gene Delivery Technology
Nonviral Genetic Medicine for Targeted Delivery
Research and Development in Genetic Medicine

Target Customers

Patients with Genetic Disorders Pharmaceutical Companies Biotech Research Institutions Healthcare Providers

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $60.75M 11
Foothill Ventures Arch Venture Partners Johnson & Johnson Innovation
Foothill Ventures, Arch Venture Partners +9
01 Dec 2022

SonoThera Alternatives & Competitors

View All Alternatives
SonoThera vs
Granza Bio
Granza Bio

Reprogramming Immunity for Target-Specific Medicines

Seed
7 employees
Biopharma, Biotechnology
Compare SonoThera vs Granza Bio
SonoThera vs
Ethris
Ethris Germany

Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe res...

Venture round
34 employees
Biopharma, Biotechnology
Compare SonoThera vs Ethris
SonoThera vs
3T Biosciences
3T Biosciences United States

3T is an immunotherapy company developing next-generation, transformative therapies for broad patien...

Series A
26 employees
Biopharma, Biotechnology
View all alternatives

FAQ About SonoThera

SonoThera is developing ultrasound-mediated nonviral genetic therapies.
SonoThera was founded in 2021.
SonoThera is headquartered in South San Francisco, United States.
SonoThera operates in Biopharma and Biotechnology. Its work centres on ultrasound-mediated therapies, nonviral genetic therapies, genetic medicine and disease treatment innovation. Its customers include Patients with Genetic Disorders, Pharmaceutical Companies and Biotech Research Institutions.
SonoThera has a B2B and B2D business model. Its revenue comes from Licensing, Service Fee and Performance Based.
SonoThera has approximately 54 employees.
SonoThera has completed 1 funding round, raising a total of $60.75M. The latest funding stage is Series A.
SonoThera offers: Development of Ultrasound-Mediated Gene Delivery Technology, Nonviral Genetic Medicine for Targeted Delivery, Research and Development in Genetic Medicine.
Top alternatives and competitors to SonoThera include Granza Bio, Ethris, 3T Biosciences, Interius BioTherapeutics, Basilard BioTech, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SonoThera and Granza Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SonoThera, https://bouncewatch.com/company/sonothera, updated 18 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes